Literature DB >> 31149513

Concurrent combination of irradiation and immune checkpoint inhibitor for recurrent pleomorphic carcinoma of the lung.

Ken Kodama1, Tomohiro Maniwa1, Yukio Kimura1, Yuriko Yagi1, Yoko Yamamoto1, Toshika Ohkawa2, Masashi Takeda3, Hiroki Kishima4, Genju Koh5, Takamasa Toyofuku6.   

Abstract

We report the case of a 49-year-old patient who developed brain, sternal, and spine metastases almost simultaneously after the radical resection of a yp-T4N0M0 pulmonary pleomorphic carcinoma of the right upper lobe following induction chemotherapy. The left occipital brain metastasis was surgically removed and followed by radiation therapy. The sternal and vertebral metastases were treated with radiation therapy. Concurrently, the immune checkpoint inhibitor nivolumab was administered. After 12 cycles of nivolumab, the two bone metastases were well-controlled. However, the brain metastasis recurred and was surgically removed again. We were able to investigate the tumor-infiltrating lymphocytes in brain metastases resected before and after radio-immunotherapy. The results revealed the increased number of CD8- and CD68-positive cells after the combined therapy compared with before the therapy. In addition, the high-level expression of program death-ligand 1 was maintained in the brain metastasis.

Entities:  

Keywords:  Immune checkpoint inhibitor; Immunotherapy; Pulmonary pleomorphic carcinoma; Radiation therapy

Year:  2017        PMID: 31149513      PMCID: PMC6498358          DOI: 10.1007/s13691-017-0315-9

Source DB:  PubMed          Journal:  Int Cancer Conf J        ISSN: 2192-3183


  4 in total

1.  Combination of Pembrolizumab With Platinum-containing Chemotherapy for Pleomorphic Carcinoma of the Lung.

Authors:  Shinichiro Okauchi; Yuika Sasatani; Toshihiro Shiozawa; Hideyasu Yamada; Kunihiko Miyazaki; Norio Takayashiki; Hiroaki Satoh
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

2.  Case Series of Pleomorphic Carcinoma of the Lung Treated With Immune Checkpoint Inhibitors.

Authors:  Kana Hayashi; Kotaro Tokui; Minehiko Inomata; Kenji Azechi; Isami Mizushima; Naoki Takata; Chihiro Taka; Seisuke Okazawa; Kenta Kambara; Shingo Imanishi; Toshiro Miwa; Ryuji Hayashi; Shoko Matsui; Satoshi Nomura; Kazuyuki Tobe
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

3.  Argon plasma coagulation with atezolizumab and chemoradiation in lung pleomorphic cancer showed a remarkable response: Case report.

Authors:  Masanori Harada; Keisuke Morikawa; Namio Kagoo; Yutaro Ito; Tsutomu Kubota; Koshiro Ichijo; Eisuke Mochizuki; Masahiro Uehara; Shun Matsuura; Kazuyo Yasuda; Masaru Tsukui; Naoki Koshimizu
Journal:  Medicine (Baltimore)       Date:  2021-05-28       Impact factor: 1.817

Review 4.  Immune Checkpoint Inhibitor Therapy for Bone Metastases: Specific Microenvironment and Current Situation.

Authors:  Chang Liu; Miao Wang; Changli Xu; Bo Li; Juxiang Chen; Jianchun Chen; Zhiwei Wang
Journal:  J Immunol Res       Date:  2021-11-28       Impact factor: 4.818

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.